Category: All

0
by in

Avantor VWR Now Offers CardioChek Plus and A1CNow+

WHITESTOWN, Ind., Oct. 4, 2023—PTS Diagnostics, a leading provider of rapid lipid, blood glucose and A1C testing devices has entered into an agreement with Avantor, a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries. This partnership will deliver upon the growing customer need for fast, accurate, and portable blood testing devices.

Biopharma and life science companies who need to regularly test and re-test lipid, glucose and A1C can purchase CardioChek Plus and A1CNow+ test systems from VWR, Avantor’s channel brand. These solutions remove the burden of scheduling and rescheduling appointments for blood draws, and often provide a more comfortable experience for patients by requiring only a fingerstick blood sample. The devices also remove some of the hassles of storage and portability of testing equipment by being small, lightweight, and battery-powered, and by allowing room temperature storage of testing materials and control solutions.

“Through our partnership with Avantor, more clinical professionals will benefit from the efficiencies that CardioChek Plus and A1CNow+ test systems have been bringing to the healthcare industry for years. Our accurate, fast, and easy-to-use blood testing systems, combined with Avantor’s market reach, will allow both companies to fulfill their shared mission of meeting the changing needs of our customers,” said Steve Riendeau, Chief Commercial Officer of PTS Diagnostics.

The partnership with Avantor will expand the availability of PTS Diagnostics flagship products to Avantor’s customers in the point-of-care testing space and will position both companies to offer more flexible solutions for a changing life sciences marketplace.

About PTS Diagnostics
PTS Diagnostics provides innovative, superior quality, point-of-care solutions.  Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for millions of patients worldwide through lipid panel screening. Our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. For more information, visit ptsdiagnostics.com.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the life sciences and technology industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.

 

PTS Diagnostics Media Contact

Laurie Gutzwiller
Vice-President Global Marketing
317-860-8070
[email protected]

 

 

 

0
by in ,

PTS Diagnostics Announces Global Distribution Partnership

Key strategic alliance as both companies work to close gaps in care for patients with chronic disease around the world.

WHITESTOWN, Ind. (May 4, 2023) – PTS Diagnostics, a U.S.-based manufacturer of point-of-care medical testing devices, announced today that they have signed a strategic distribution agreement with BIOSYNEX S.A.

“PTS Diagnostics is very happy to announce our important global distribution partnership with BIOSYNEX S.A. BIOSYNEX is a global leader in diagnostic testing providing a broad portfolio of products across many sectors of healthcare, many of which PTS does not serve today. PTS’ CardioChek® and A1CNow®+ product lines are a perfect complement to the current BIOSYNEX portfolio, and this partnership will position both companies to grow our point-of-care (POC) lipid and A1C businesses. Most importantly, the partnership with PTS will allow BIOSYNEX customers to expand their offerings in the cardiovascular and diabetes space, both growing and costly disease states globally. PTS considers BIOSYNEX a valuable complimentary partner to our current sales team and world class distribution network and we are incredibly excited about the future of this relationship and what it means for patients around the world.” said Steve Riendeau, Chief Commercial Officer of PTS Diagnostics.

“Our collaboration with PTS Diagnostics has greatly contributed to making BHR pharmaceutical part of BIOSYNEX group a key player in UK with more than 12 000 devices placed and more than 4.5M tests since 2009. This new agreement is a major step in our partnership because it opens up important commercial development opportunities in cardiovascular and diabetes diagnostics by giving us access to new applications in new territories.” said Larry Abensur, Chairman and CEO of BIOSYNEX S.A.

About PTS Diagnostics
PTS Diagnostics provides innovative, superior quality, point-of-care solutions.  Healthcare professionals have used our CardioChekÒ products to assess cardiovascular disease risks for millions of patients worldwide through lipid panel screening. Our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. For more information, visit ptsdiagnostics.com.

 

About BIOSYNEX S.A.
Specializing in the design and distribution of rapid diagnostic tests in France and in more than 90 countries, BIOSYNEX, a French Laboratory, created in 2005, offers healthcare solutions that improve the overall treatment of patients. For more information visit BIOSYNEX.com

###

Press Contact:
Laurie Gutzwiller
Vice-President Global Marketing
317-860-8070
[email protected]

0
by in

Bridge Purchasing Solutions Joins the PreVantage™ Partnership Network

Key strategic alliance as both companies work to close gaps in care for patients with chronic disease.

WHITESTOWN, Ind. (September 30, 2021) – PTS Diagnostics, a U.S.-based manufacturer of point-of-care medical testing devices, announced today that they have signed a strategic alliance agreement with Bridge Purchasing Solutions Inc. 

“Bridge has built a very unique digital voucher platform that helps payors and businesses who have employees that need point-of-care testing to provide increased access while closing critical care gaps related to cardiovascular disease and diabetes,” said Steve Riendeau, Chief Commercial Officer of PTS Diagnostics. “As a result of the pandemic, many people have been unable to get important annual biometrics such as cholesterol and A1C testing.  The Bridge platform allows electronic vouchers to be sent to an individual’s mobile phone where they can take it to a participating retail pharmacy to get the tests conducted. The platform also allows for seamless redemption of incentives which often accompany this testing. The PreVantage Partnership Network is focused on bringing companies together with a common mission of closing gaps in care for patients with chronic diseases and this is another opportunity for us to do so.  PTS feels strongly that this strategic alliance is a great fit for our customers.” 

PTS is a global leader in the production and distribution of point-of-care solutions. “It’s a privilege to be part of the PreVantage Network.” said Ken Erickson, CEO of Bridge Purchasing Solutions.  “Our next generation B2B2E (Business to Business to Employee) fintech platform makes it possible to issue digital payment cards directly to an employee which can only be redeemed at the specified retail pharmacy partner.  The frictionless payments, compliance reporting along with increased adherence are also keys to our future success.  When combined with the world class products from PTS we are convinced our clients will embrace the solution.”  

 

About PTS Diagnostics
PTS Diagnostics provides innovative, superior quality, point-of-care solutions.  Healthcare professionals have used our CardioChek. products to assess cardiovascular disease risks for millions of patients worldwide through lipid panel screening. Our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. For more information, visit ptsdiagnostics.com. 

About Bridge Purchasing Solutions
Bridge, an innovative FinTech company, is on a mission to remove the barriers that hinder compliance with a healthy lifestyle including education, access, and cost. Bridge works with employers, health plans, and other health advocates to educate and drive employees and members to low-cost retail providers. The bridge platform can be used to drive compliance with health activities such as immunizations and biometric screenings, encourage healthy food choices, track ongoing management of at-risk members and deliver reward incentives in near real time. To find out how Bridge can help you and your organization achieve your healthcare goals vision Bridgepurchasingsolutions.com or email [email protected]. 

 

Press Contact:
Laurie Gutzwiller 
Executive Director, Marketing
317-870-8070
[email protected]

0
by in

Why You Need Both A1C and Glucose Tests for Diabetes

If you have diabetes, your doctor has likely asked you to measure your blood sugar level several times a day and to have your A1C tested 2 to 4 times per year. Have you ever wondered why you need both?

It may seem that providing months-worth of daily blood glucose logs would provide more than enough information for your doctor to evaluate your treatment plan. But in fact, daily blood glucose measurements only tell part of the story. To get the full story, you also need an A1C test, which measures your average blood sugar levels over the past 2-3 months.

The Difference Between Blood Glucose and A1C

To help make sense of it all, let’s think of your blood glucose and A1C goals in terms of saving money. Say you have a goal of saving $10,000 for an emergency fund. To help you reach your goal, you decide to keep a daily log of each time you spend. In 3 months, as you look back over your logs you notice that when you go to your favorite department store, you tend to spend about $50 more than you would like. To stay on track with your savings goal, you adjust your behavior. Maybe you decide to stop going to that department store, or to make a list before you shop to reduce impulse purchases.

That’s the type of benefit you and your healthcare providers get from daily blood glucose measurements. It can show you how well-controlled your blood sugar was on a particular day, at a particular time during that day.

Now, let’s say you want to see how close you are to your financial savings goal overall. For that, you’ll need to take a look at your bank account to see how well those day-to-day behavioral adjustments have been paying off over time. Has consistently avoiding your favorite department store allowed you to save up as much money as you’d hoped? If not, what additional adjustments could you make in your day-to-day decisions to get you closer to that goal?

That’s the type of benefit you and your healthcare providers get from A1C test results. Since it gives you an average of your blood glucose levels over the last 2-3 months and takes into account those level fluctuations across every hour of the day, you get a clearer picture of the impact of your overall diabetes management strategies.

A1C Has the Power to Predict

In a nutshell, blood glucose monitoring is great for giving you feedback on how your daily choices—foods, activities, etc.—are affecting your diabetes management in the short term. A1C tells you what kind of impact those choices are having on your diabetes management overall. And, understanding that overall impact helps you and your doctor evaluate your risk for developing complications from diabetes. For example:

  • An ongoing diabetes study in the UK has found for each 1% decrease in a person’s A1C, there’s a 35% decrease in the risk of developing eye disease and kidney disease.1

A1C at Home

Before the COVID-19 pandemic, A1C tests were often conducted in doctor’s offices or stand-alone laboratories. But just as people have begun to adapt by attending virtual appointments from the comfort and safety of their homes, they have also begun to conduct their own blood tests at home. This has led to a boom in new at-home tests3, for everything from A1C to food sensitivities. Fortunately, for patients with diabetes, this means that they don’t have to miss out on the benefits of regular A1C testing, even when they can’t get blood work done in person.

Before you purchase an at-home A1C test, speak with your doctor to determine which FDA-cleared A1C test is best for you.

Sources

1 https://www.medscape.com/answers/117853-6490/what-are-the-implications-of-the-findings-of-the-united-kingdom-prospective-diabetes-study-ukpds-for-management-of-type-2-diabetes-mellitus-dm

2 https://www.endocrinologyadvisor.com/home/topics/diabetes/type-2-diabetes/hemoglobin-a1c-can-predict-cardiovascular-outcomes-in-high-risk-patients-with-diabetes/

3 https://medicalfuturist.com/the-rise-of-at-home-lab-tests/

0
by in

PTS Diagnostics and MedPro Healthcare Sales Solutions Enter Into Partnership

PTS Diagnostics and MedPro Healthcare Sales Solutions Enter Into Partnership

Effective immediately, augments existing accomplished sales force

WHITESTOWN, Ind. (April 1, 2020) – PTS Diagnostics, a U.S.-based manufacturer of point-of- care medical testing devices announced today that they are partnering with MedPro Healthcare Sales Solutions, a leading healthcare contract sales organization.

The partnership adds positions to the existing PTS Diagnostics sales force. These new representatives will be strategically staggered throughout the country and managed by PTS Diagnostics directors and senior sales managers. Together they’ll be responsible for expanding the footprint of the CardioChek® and A1CNow® product lines.

“MedPro’s support is crucial to achieving our core mission of closing gaps in care and potentially improving the outcomes of individuals with chronic conditions such as diabetes and cardiovascular disease,” said Cliffe Allen, VP of U.S. Sales of PTS Diagnostics. “Their knowledge regarding point-of-care testing combined with exceptional distribution relationships positions us for ongoing success in numerous vertical markets.”

MedPro was founded in 2006 and has grown into a leading sales force that’s trusted by manufacturers and distributors of all sizes. Their team’s connections span across a wide spectrum of healthcare delivery models, allowing for a streamlined sales cycle.

PTS Diagnostics’ solutions represent the first and only point-of-care lipid, glucose, and HbA1c tests sold by MedPro representatives.

“We’re thrilled to partner with PTS Diagnostics and believe that the certified accuracy, precision, and speed of their solutions will be a value add for physician offices, pharmacies, walk-in clinics, and more,” said Manny Losada, President of MedPro Healthcare Sales Solutions. Together we hope to positively impact at-risk populations at the point of care.

This announcement comes on the heels of PTS Diagnostics’ recent A1CNow+ Controls™ product launch and it precedes future 2020 product announcements.

To learn more about PTS Diagnostics or to connect with a sales representative, email: [email protected], or call 877-870-5610.

About PTS Diagnostics

Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek products to assess cardiovascular disease risks for millions of patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. For more information, visit ptsdiagnostics.com.

About MedPro Healthcare Sales Solutions

Med-Pro Associates is a nationwide independent rep group specializing in representing leading manufacturers across the country who sell their products both through distribution and direct to the hospital, long term care, physician, dental and veterinary markets.

Press Contact

Ryan Simpson, Marketing Communications
317-870-5610 –  [email protected]